Follow-The-Filings

Security · featured owners

ETON Eton Pharmaceuticals Inc.

COM Equity as of 2026 Q2 among managers we track

  • 2 Owners
  • Max 9.4%
  • $105M
  • 1 add

Who owns this now

Largest portfolio weights among featured holders · max 9.4% (James Silverman - Opaleye...) · not free-float ownership

  1. James Silverman 9.4%
  2. Polen Capital Management add 0.01%

holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

history
James Silverman - Opaleye Management 2026 Q2 9.4% Hold 2,860,000 $104M history
Polen Capital Management 2026 Q2 0.01% Add +50.6% 45,379 $2M history

2 current · options excluded

SEC filings

Recent issuer filings from EDGAR · 18 shown · open Filing / Doc on SEC.gov

Filed Form Detail Links
8-K 2.02,9.01 Filing Doc
10-Q FORM 10-Q Filing Doc
8-K 1.01,2.01,9.01 Filing Doc
8-K 5.02 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 5.07 Filing Doc
8-K 1.01,2.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q FORM 10-Q Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
8-K 1.01,2.03,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-K FORM 10-K Filing Doc
8-K 1.01,2.01,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc

Insider forms

Form 3 / 4 / 5 from EDGAR · 22 shown

Filed Form Detail Links
4 Period Aug 24, 2026 Filing Doc
4 Period Aug 19, 2026 Filing Doc
4 Period Jul 31, 2026 · 8 forms Filing Doc
4/A Period Jul 14, 2026 Filing Doc
4 Period Jul 14, 2026 Filing Doc
4 Period Jul 12, 2026 Filing Doc
4 Period Jul 12, 2026 Filing Doc
4 Period Jul 2, 2026 Filing Doc
4 Period Jun 26, 2026 Filing Doc
4 Period Jun 17, 2026 Filing Doc
4 Period May 28, 2026 Filing Doc
4 Period May 22, 2026 Filing Doc
4 Period Apr 21, 2026 Filing Doc
4 Period Feb 3, 2026 Filing Doc
4 Period Jan 12, 2026 Filing Doc

Updated 2 days ago Source: SEC EDGAR submissions All on EDGAR

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $31.64M $39.01M $79.95M
Gross profit $21.06M $23.41M $42.74M
Gross margin * 66.6% 60.0% 53.5%
Net income -$936,000 -$3.82M -$4.6M
Net margin * -3.0% -9.8% -5.8%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $26.84M $41.02M $60.58M
Total non-current assets * $4.9M $35.1M $31.53M
Total assets $31.74M $76.12M $92.11M
Total current liabilities $16.24M $19.95M $38.49M
Total non-current liabilities * $22,000 $31.75M $27.47M
Total equity $15.48M $24.43M $26.15M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $6.82M $969,000 $10.52M
Cash from investing -$775,000 -$40.01M -$333,000
Cash from financing -$957,000 $32.59M $815,000
Net change in cash $5.08M -$6.45M $11.01M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders